YZYaroslav A. Zhulikov

Yaroslav A. Zhulikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaroslav A. Zhulikov has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of somatostatin receptor expression in patients with pulmonary and thymic neuroendocrine neoplasms. First results of a single-center study

    by M. A. Vorobeva, V. V. Delektorskaya, E. V. Evdokimova, Ya. A. Zhulikov, A. A. Markovich, V. A. Gorbunova, A. V. Egorova, E. V. Artamonova, P. V. Kononets, М. А. Воробьева, et al.

    Background . Pulmonary and thymic neuroendocrine neoplasms (NENs) are divided into a group of well-differentiated neuroendocrine tumors (NETs), including typical and atypical carcinoids (TC and AC), and a group of poorly differentiated neuroendocrine carcinomas (NECs), including large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). According to the 2022 WHO classification of thoracic NENs, AC are subdivided into two groups: AC with a low mitotic index (MI) (AC G2) and AC with an elevated MI (AC G3). Russian experts distinguish well-differentiated pulmonary and thymic neuroendocrine tumors (NETs), including TC (analogous to gastrointestinal NET G1), AC with Ki‑6730% (AC G3) (by analogy with gastrointestinal NET G2 and G3), and neuroendocrine carcinomas (LCNEC and SCLC). Data on the expression of somatostatin receptors (SSTR) subtypes 2 and 5 in thoracic NENs remain limited. Aim . To compare the expression of SSTR2A and SSTR5 using immunohistochemistry (IHC) and 68Ga-DOTATATE PET/CT. Materials and methods . The study included 173 patients with thoracic NENs. SSTR status was determined in 133 cases (76.9%): by IHC in 65.4% (n=87) and by 68Ga-DOTATATE PET/CT in 62.4% (n=83). Results . In the TC subgroup, SSTR positivity by IHC was detected in 66.7% of cases; in AC G2–46.5%, AC G3–70%, and LCNEC – 38.5%. SSTR2A expression was the most frequently observed. Using 68Ga-DOTATATE PET/CT, SSTR positivity was detected in 82.4% of TC cases, 86% of AC G2, 100% of AC G3, and 100% of LCNEC. The discordance rate between IHC and PET/CT was 41.7% (p=0.074). Overall survival decreased with increasing Ki‑67 (pConclusions . 68Ga-DOTATATE PET/CT demonstrates higher sensitivity for detecting SSTR expression, however, IHC may identify additional isolated IHC-positive cases.

  • Open Access

    Retrospective analysis of BUCEN score prognostic value in Russian population of patients with advanced adrenocortical carcinoma treated with platinum-based chemotherapy in combination with mitotane

    by Ya. A. Zhulikov, E. V. Artamonova, A. Yu. Kolycheva, E. I. Kovalenko, V. Yu. Bokhyan, E. V. Evdokimova, E. S. Kolobanova, O. A. Martynova, D. V. Rogozhin, V. A. Gorbunova, et al.

    Introduction. Currently, the algorithm for selecting first-line treatment for advanced adrenocortical carcinoma (ACC) is not clearly defined; the choice between mitotane monotherapy and its combination with platinum-based chemotherapy remains controversial. In a large retrospective study (n = 439), the BUCEN scoring system was proposed as a predictor of treatment response, which could help determine first-line therapy [9]. Our study aimed to evaluate the prognostic value of the BUCEN scores in the Russian population of patients with advanced ACC, treated with a combination of platinum-based chemotherapy and mitotane. Materials and Methods. This retrospective single-center study included patients aged ≥ 18 years with advanced ACC and pre-assessed BUCEN scores who received platinum-based chemotherapy in combination with mitotane at the N. N. Blokhin National Medical Research Center of Oncology between 2016 and 2025. Result. The study included 63 patients with BUCEN scores of 0–2 (n = 31; 49.2 %) and ≥ 3 (n = 32; 50.8 %). Fifty patients (79.4 %) received etoposide + cisplatin + doxorubicin (EDP), 5 patients (7.9 %) received etoposide + cisplatin (EP), and 8 (12.7 %) received etoposide + carboplatin (EC). Therapeutic serum levels of mitotane were achieved in 42 patients (66.7 %). The objective response rate (ORR), disease control rate (DCR) at ≥ 6 months, and DCR at ≥ 12 months were 20.6 %, 62.3 %, and 26.3 %, respectively. A BUCEN score of 0–2 was associated with an improved ORR (p = 0.03), a DCR at ≥ 6 months (p < 0.01), and a DCR at ≥ 12 months (p = 0.03). A multivariate analysis revealed that non-anthracycline regimens in patients with BUCEN ≥ 3 were associated with a statistically significant decrease in progression-free survival (PFS) and overall survival (OS). A statistically significant OS improvement was observed in patients with recurrence-free survival of ≥ 12 months post-adrenalectomy (p = 0.04). Conclusion. The BUCEN scoring system is reproducible, simple to use, and could be applied for the stratification of patients with advanced ACC. Implementation of this system in clinical practice to pre-select patients for mitotane monotherapy as a first-line treatment requires prospective validation. The significantly poorer outcomes in the EP / EC group may partly reflect patient characteristics, as these regimens were used in those with contraindications to anthracyclines or cisplatin. However, based on our data, we do not recommend non-anthracycline regimens in patients without contraindications to EDP chemotherapy.

  • Open Access

    Surgical treatment of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava: a post-hoc analysis and series of clinical cases

    by Maryam R. Tamrazova, Тамразова Марьям Романовна, Vagan Yu. Bokhian, Бохян Ваган Юрикович, Merab M. Gabrava, Габрава Мераб Мерабович, Yaroslav A. Zhulikov, Жуликов Ярослав Андреевич, Kazbek A. Batyrov, Батыров Казбек Ахмедович, et al.

    Aim. To describe the surgical approach and evaluate the results of treatment in a series of cases of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava (IVC). Materials and methods. The study presents the experience with surgical treatment of patients with pheochromocytoma complicated by IVC tumor thrombosis. From 1989 to 2024, 181 patients with pheochromocytoma underwent surgical treatment at the Blokhin National Medical Research Center of Oncology, of whom 7 (3.9%) had an IVC involvement. In 6 cases, the patients were males aged 17 to 73 years, and in 1 case, a female aged 66 years. In all cases, tumor thrombosis of the IVC was due to right-sided pheochromocytoma, including in 1 patient with bilateral adrenal gland involvement. Pheochromocytoma was diagnosed based on clinical, laboratory, and imaging data (CT scan, combined positron-emission and CT scan, and magnetic resonance imaging) and confirmed by histological and immunohistochemical studies. Surgical approach included radical removal of the tumor with thrombectomy from the IVC in 4 patients. In 2 cases, exploratory interventions were performed, and 1 patient received drug treatment. Particular attention is paid to the surgical procedure, which requires careful planning and an individual approach to each patient. The surgery includes the technique of removing blood clots with their full visualization due to the structure of tumor thrombi and the risk of fragmentation and embolism. Results. No postoperative mortality was reported. During follow-up (up to 5 years), no recurrence or progression was detected in the patients. Conclusion. Tumor thrombosis of the IVC in pheochromocytoma is uncommon. Surgery is the treatment of choice, providing radical tumor removal and achieving long-term remission in pheochromocytoma. Particular attention should be paid to the characteristics of the tumor thrombi, which, according to our observations, have a loose consistency and often a tight attachment to the vascular wall, increasing the risk of fragmentation. Therefore, thrombectomy should be performed with careful visualization and control of all thrombotic masses to minimize intraoperative embolism.

  • Open Access

    The Role of Platinum Agents in Neoadjuvant Chemotherapy for BRCA-Associated Triple-Negative Breast Cancer: Preliminary Results of a Single-Center Study

    by Елена Игоревна Коваленко, Элина Венеровна Янгирова, Ярослав Андреевич Жуликов, Андрей Константинович Новиков, Владимир Александрович Федько, Мария Владимировна Дулаева, Татьяна Александровна Титова, Анна Михайловна Строганова, Татьяна Сергеевна Лисица, Елена Владимировна Артамонова

    Введение. Рак молочной железы, ассоциированный с герминальными мутациями BRCA1/2, характеризуются дефицитом гомологичной рекомбинации, что определяет их повышенную чувствительность к ДНК-повреждающим агентам, включая препараты платины. Однако роль платиносодержащих режимов в неоадъювантной химиотерапии (НАХТ) у данной категории пациенток остается дискутабельной. Цель. Оценить влияние включения препаратов платины в схемы НАХТ на частоту достижения полной патоморфологической регрессии (pCR) у пациенток с gBRCA1/2-ассоциированным тройным-негативным раком молочной железы (ТНРМЖ). Материалы и методы. Проведен анализ проспективно ведущейся базы данных с контрольной ретроспективной когортой. В одноцентровое исследование включены 232 пациентки с gBRCA1/2-ассоциированным ТНРМЖ II–III стадии, получившие НАХТ с последующим хирургическим лечением. Пациентки были разделены на группы в зависимости от режима лечения: антрациклин-таксан-платиносодержащая НАХТ (n = 169) и антрациклин-таксан-содержащая НАХТ без платины (n = 63). Первичной конечной точкой являлась частота полных патоморфологических ответов (pCR/RCB 0). Результаты. Частота pCR в группе платиносодержащей НАХТ составила 63,3 % против 41,3 % в группе без платины (ОШ 2,46; 95 % ДИ 1,36–4,43; p = 0,03). Наиболее выраженное преимущество от добавления платины отмечено у пациенток со II стадией заболевания (ОШ 2,63; p = 0,008), при наличии частых мутаций BRCA1/2 (ОШ 2,67; p = 0,013) и при использовании стандартного режима AC по сравнению с дозоуплотненным (ОШ 2,72; p = 0,022). В подгруппе редких мутаций, а также при дозо-уплотнённой НАХТ статистически значимых различий не выявлено. Для наиболее распространённой мутации gBRCA1 5382insC преимущество платины не достигало статистической значимости. В подгруппе еженедельного паклитаксела отмечена тенденция к увеличению частоты pCR без достижения статистической значимости (ОШ 2,04; p = 0,051). Выводы. Включение препаратов платины в схемы НАХТ у пациенток с gBRCA1/2-ассоциированным ТНРМЖ ассоциировано со статистически значимым увеличением частоты pCR. Наибольший эффект наблюдается в отдельных клинико-генетических подгруппах, что подчеркивает необходимость дальнейшей персонализации терапии. Полученные результаты требуют подтверждения в более крупных проспективных исследованиях.

  • Open Access

    Long-term outcomes of combined surgery for locally advanced and metastatic adrenocortical carcinoma: a 35-year experience analysis

    by Mirzo R. Mirzoev, Vagan Y. Bokhyan, Vladislav E. Bugaev, Yaroslav A. Zhulikov, Mariam R. Tamrazova, Ivan S. Stilidi

    Background. Adrenocortical carcinoma (ACC) is a rare malignancy characterized by aggressive behavior and poor prognosis. Radical resection remains the only curative treatment, yet locally advanced disease with invasion of adjacent organs and major vessels frequently necessitates combined and multiorgan resections. Evaluating the outcomes and safety of such aggressive surgical approaches is essential to refine treatment strategies and indications. Aim. To evaluate the outcomes and prognostic factors of combined resections in patients with stage III–IV adrenocortical carcinoma, including procedures with vascular and multiorgan involvement. Materials and methods. This retrospective study was conducted at the Blokhin National Medical Research Center of Oncology and included 192 patients with stage III–IV adrenocortical carcinoma who underwent surgery between 1987 and 2022. A detailed analysis was performed for 115 patients who underwent combined resections involving adjacent organs and/or major vessels. For comparison, data from 42 standard adrenalectomies and 13 exploratory interventions were analyzed; an additional group of 20 patients received non-surgical treatment. Survival was assessed using the Kaplan–Meier method, and independent prognostic factors were identified using Cox proportional hazards regression (p 0.05). Results. Among 115 patients who underwent combined resections, postoperative complications occurred in 55.6% versus 16.6% after standard operations (p = 0.0001); postoperative mortality rates were 11.4% and 2.4%, respectively. Radical (R0) resections were associated with significantly better survival: median overall survival reached 84 months versus 4 months after palliative procedures (p 0.01). In stage IV disease, the best outcomes were observed in patients who achieved R0 resection limited to the abdominal cavity (median 41 months), compared to 8 and 11 months after conditionally radical and R2 resections, respectively (p = 0.004). Multivariate analysis confirmed the prognostic significance of resection radicality as prognostic factor. Conclusion. Radical resection remains the key determinant of survival in patients with stage III–IV adrenocortical carcinoma. Our analysis confirms that combined surgical procedures, despite their technical complexity and higher risk of complications, are justified and provide a significant improvement in long-term outcomes for this patient population.

  • Open Access

    Retrospective non-comparative single-center study of platinum-based regimen efficacy in the 1st line therapy of high-grade neuroendocrine carcinomas of gynecologic tract

    by Khadizhat A. Suleymanova, Ya. A. Zhulikov, E. V. Evdokimova, A. S. Shevchuk, A. K. Kachmasova, V. V. Delektorskaya, A. A. Markovich, I. S. Stilidi, E. V. Artamonova

    Introduction. Neuroendocrine carcinomas (NEC) of gynecologic tract are rare and aggressive tumors for which there are currently no standardized approaches to systemic therapy. Platinum-based chemotherapy regimens are the main treatment method, but data on their efficacy are limited to a few retrospective studies. Aim. To evaluate the efficacy of platinum-based chemotherapy as first-line treatment for patients with metastatic gynecologic NEC, as well as the prognostic role of tumor histology, tumor location, disease extent, frequency of second-line therapy, and progression-free survival (PFS). Materials and methods. A retrospective analysis was conducted of the efficacy of platinum-based chemotherapy as first-line therapy for primary metastatic or recurrent (with a platinum-free interval ≥12 months) NEC of gynecologic tract at the N. N. Blokhin National Medical Research Centre for Oncology in 2017–2024. Results. The most common site of primary tumor was the cervix (n = 18; 62.1 %), 5 patients had ovarian NEC (17.2 %), 3 had uterine NEC (10.3 %), 2 had vulvar NEC (6.9 %), and 1 case of vaginal NEC was diagnosed (3.4 %). In 15 patients (51.7 %), the disease was detected at stage IV, and in 14 (48.3 %), progression was noted after primary treatment with a platinum-free interval of ≥12 months. Small-cell histological type was detected in 17 patients (58.6 %), large-cell in 12 of 29 (41.4 %). The frequency of high microsatellite instability (MSI) cases was 13.3 % (2 out of 15 examined), and positive expression of somatostatin receptors 2 and / or 5 (SSTR) was found in 33.3 % (4 out of 12 examined). In most cases, etoposide + cisplatin / carboplatin regimens were used (n = 25; 86.2 %), and 4 patients (13.8 %) received the paclitaxel + carboplatin regimen. The objective response rate was 44.8 %; the median PFS was 7.5 months (95 % confidence interval (CI) 2.9–12.1), median overall survival (OS) was 14 months (95 % CI 13–16.2). Disease control ≥6 months was achieved in 15 (51.7 %) patients, ≥12 months in 6 (20.7 %). Peritoneal carcinomatosis was significantly associated with worse PFS (hazard ratio 4.37; p = 0.01), and ECOG status 1–2 was associated with worse OS (hazard ratio 3.4; p = 0.01). No statistically significant differences in survival were found between histological types. Conclusion. First-line platinum-based chemotherapy demonstrates efficacy comparable to previously published data in metastatic NEC of gynecologic tract. The high frequency of MSI-high cases justifies its routine measurement. The expression of somatostatin receptors is of interest for further study as a prognostic and therapeutic marker.

  • Open Access

    Efficacy of mFOLFIRINOX chemotherapy for treatment of high-grade G3 neuroendocrine tumors and gastroenteropancreatic neuroendocrine carcinomas

    by Abidat K. Kachmasova, Ya. A. Zhulikov, E. V. Evdokimova, K. R. Gadzhieva, M. A. Vorobyova, Kh. A. Suleymanova, V. V. Delektorskaya, G. S. Emelyanova, А. А. Markovich, О. А. Martynova, et al.

    Background. Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC) are rare tumors. Despite the differences in genetic characteristics, treatment principles for GEP-NECs are extrapolated from lung NECs. A small retrospective study demonstrated potential effectiveness of the mFOLFIRINOX regimen. Aim. To evaluate the efficacy of mFOLFIRINOX ± somatostatin analogues in treatment of inoperable or metastatic G3 Ki-67 ≥55 % GEP-NECs and neuroendocrine tumors (NETs) in a prospective cohort. Materials and methods. A prospective single-center phase II trial with the Simon’s two-stage design was conducted. The primary endpoint was disease control (DC) ≥6 months. The statistical hypothesis was that the mFOLFIRINOX regimen would increase the disease control rate from 50 % (historical control) to 70 %. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). In the 1st stage, 16 patients were planned for enrollment. If ≥9 patients achieved DC ≥6 months, the cohort would be expanded to 39 patients. Inclusion criteria: patients ≥18 years with histologically confirmed G3 Ki-67 ≥55 % GEP-NEC or NET, ECOG performance status 0–2. Patient enrollment took place between 2019 to February of 2024. Results. Sixteen patients were included in the study (12 men, 4 women). The most common primary tumor sites were the stomach (8 patients, 50 %) and pancreas (5 patients, 31.3 %). Large-cell NEC was diagnosed in 10 patients (62.5 %), small-cell NEC in 1 patient (6.3 %), and G3 NET in 5 patients (31.3 %). Median Ki-67 index was 70 % (range 40–95 %). Stage IV disease was diagnosed in 15 patients (93.7 %), and 1 patient (6.3 %) had unresectable gastric NEC. The liver was the most frequent site of metastases (n = 11, 68.8 %), with isolated liver involvement in 9 patients (56.3 %). ECOG performance status was 0–1 in 15 patients (93.7 %). The majority (n = 14, 87.5 %) of patients received mFOLFIRINOX as 1st line treatment. Positive expression of somatostatin receptors SSTR2A / 5 was found in 7 patients (43.7 %), who additionally received somatostatin analogues. ORR was 62.5 % (n = 10), and stable disease was observed in 37.5 % (n = 6) of patients. Disease control ≥6 months was achieved in 93.7 % of patients (n = 15). With a median follow-up of 13.2 months, median PFS was 10.8 months (95 % confidence interval 7.57–14.1). One serious adverse event (myocardial infarction) was reported. No grade V toxicity was observed. Conclusion. mFOLFIRINOX chemotherapy demonstrated promising results in treatment of G3 Ki-67 ≥55 % GEP NECs and NETs. The primary endpoint was met, and the study is ongoing.

  • Open Access

    Prospective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancer

    by Ярослав Андреевич Жуликов, Елена Владимировна Артамонова, Елена Игоревна Коваленко, Ваган Юрикович Бохян, Анна Александровна Рослякова, Екатерина Вадимовна Евдокимова, Кизлер Рифкатовна Гаджиева, Ольга Андреевна Мартынова, Евгения Сергеевна Колобанова, Иван Сократович Стилиди

    Введение. Комбинация химиотерапии EDP (этопозида, доксорубицина, цисплатина) с митотаном является стандартом первой линии терапии адренокортикального рака (АКР). Достижение терапевтических концентраций митотана связано с улучшением выживаемости без прогрессирования (ВБП) и общей выживаемости (ОВ) в ряде исследований. В большинстве опубликованных работ схема назначения митотана определялась локальными протоколами, что подчеркивает необходимость валидации протокола по его назначению и создания унифицированного режима дозирования. Материалы и методы. Проведено одноцентровое проспективное исследование II фазы с использованием двухэтапного дизайна Симона. В исследование включали пациентов с местнораспространенным или метастатическим АКР, ECOG 0–1, ранее не получавших митотан. Первичная конечная точка — частота достижения терапевтической концентрации митотана (14–20 мкг/мл). Статистическая гипотеза предполагала увеличение частоты достижения терапевтической концентрации с 50 до 70 % (β = 0,2; α = 0,05). Вторичные конечные точки — частота объективного ответа и контроля болезни ≥ 6 мес, ВБП, ОВ, безопасность терапии. Митотан назначался в начальной дозе 2 г/сут с постепенной эскалацией каждые 3-5 дней на 0,5 г до 4 г/сут, с последующей коррекцией дозы в зависимости от его концентрации в крови. Все пациенты одновременно с митотаном получали стандартную платиносодержащую химиотерапию (EDP или EP/EC). Результаты. В исследование включено 47 пациентов: 27 мужчин (57,4 %) и 20 женщин (42,5 %). Все пациенты получали платиносодержащую химиотерапию — 45 (95,8 %) EDP, 2 — EP/EC. При медиане наблюдения 12,4 мес терапевтическая концентрация митотана достигнута в 72,3 % (n = 34) случаев, медиана времени до ее достижения — 4,3 мес (95 % ДИ 3,3–5,3 мес). Частота объективного ответа составила 29,7 % (n = 14), контроль заболевания ≥ 6 мес — 63,8 % (n = 30). Медиана ВБП — 8,4 мес (95 % ДИ 4,2–12,6), медиана ОВ — 24,6 мес (9,9–44,6). Профиль нежелательных явлений не отличался от ранее описанного. Выводы. Разработанный режим митотана обеспечивает быстрое и безопасное достижение терапевтической концентрации у большинства пациентов и может быть рекомендован для рутинной практики.


  • Pheochromocytomas and paragangliomas in patients with congenital heart defects

    by V. Y. Bokhian, T. Y. Danilov, M. R. Tamrazova, M. M. Gabrava, Y. A. Zhulikov, A. R. Shin, A. M. Mikhaylova

    The correlation between pheochromocytoma/paraganglioma (PHEO/PGL) and cyanotic congenital heart defects is rare but not coincidental. Research suggests that the development of PHEO/PGL in these patients maybe explained by chronic hypoxia, disruptions in the sympathetic nervous system, and potential genetic predisposition. These factors may provoke the tumor transformation of chromaffin cells. Additionally, diagnosing PHEO/PGL in patients with heart defects is complicated by hemodynamic disturbances that mask the characteristic sympathoadrenal crises of PHEO/PGL. The occurrence of these neoplasms can exacerbate the clinical course of congenital defects due to increased catecholamine secretion, leading to vasoconstriction and worsening hypoxia. We present two clinical cases of PHEO/PGL in the context of congenital heart defects, with patients observed and treated at the N.N. Blokhin National Medical Research Center of Oncology and the A.N. Bakoulev National Medical Research Center of Cardiovascular Surgery. These observations emphasize the importance of vigilance for symptoms of tachycardia and uncontrolled hypertension in such patients. Despite their rarity, the relationship between these pathologies must be considered for accurate diagnosis and optimal treatment selection.

  • Open Access

    Interim Results of a Phase I/II Clinical Study to Assess the Safety And Efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-TATE Produced by the N.N. Blokhin National Medical Research Center of Oncology in Patients with Neuroendocrine Neoplasia

    by O. D. Baranova, A. S. Krylov, Yа. A. Zhulikov, E. V. Artamonova, A. A. Markovich, D. V. Likhosherstova, A. V. Filimonov, P. E. Tulin, B. I. Dolgushin, I. S. Stilidi

    Introduction : Peptide-receptor radionuclide therapy (PRRT) is currently a well-studied treatment option for patients with neuroendocrine tumors. Based on the results of the Phase III NETTER-1 and NETTER-2 trials, 177 Lu-DOTA-TATE therapy has become the standard for second- and subsequent-line therapy. However, there are currently no domestic studies investigating PRRT. In our study, we evaluated the efficacy and safety of 177 Lu-DOTA-TATE, a radiopharmaceutical drug synthesized in the cyclotron-radiochemistry laboratory of the Department of Radionuclide Diagnostics and Therapy at the N.N. Blokhin National Medical Research Center of Oncology and having undergone preclinical trials, in patients with neuroendocrine neoplasias (NENs). Materials and Methods : This phase I/II study enrolled patients with metastatic NENs of various locations with Ki-67 177 Lu-DOTA-TATE radiopharmaceutical every 8–10 weeks, along with extended-release somatostatin analogs. The primary endpoints were response rate (disease control) of ≥​​ 6 months and safety. Secondary endpoints were objective response rate, progression-free survival (PFS), and overall survival (OS). Patients were enrolled from June 2024 to July 2025. This study analyzes the Įrst 11 patients enrolled in the study. Results : Eleven patients were included in this analysis. The median age was 54 years. Primary tumor localizations: gastroenteropan‑ creatic (GEP) NEN — 6 patients (54.5 %), pheochromocytomas/paragangliomas — 3 patients (27.3 %), lung NEN and NEN metastases from the esophagus — 1 patient each (9.3 %). Median Ki-67 was 10 % (5–25 %). All patients had previously received everolimus therapy, 9 patients (81.8 %) — chemotherapy. The objective response rate (ORR) was 54.5 %, all responses were partial. Disease stabilization (DS) was recorded in 36.4 %. Disease control (DC) ≥​​ 6 months was noted in 90.9 % of cases. Median PFS and OS with a median follow-up of 11.3 months were not achieved. Grade 3–4 leukopenia was recorded in 2 patients (18.2 %). No decrease in renal function was noted. One serious adverse event associated with disease progression was recorded: pleurisy, requiring thoracentesis for fluid evacuation. Conclusion : Peptide-receptor radionuclide therapy with 177 Lu-DOTA-TATE, manufactured at the Blokhin National Medical Research Center of Oncology, resulted in high ORR and CFS rates in patients with NEN of various locations. Clinically signiĮcant myelosuppres‑ sion was observed in 18.2 % of cases.